Fuse-AI secures EU regulatory approval

Fuse-AI has secured EU Medical Device Regulation (MDR) for its AI software, Prostate.Carcinoma.ai. The clearance allows Fuse-AI to distribute the software as a medical product, the company said.

Prostate.Carcinoma.ai automatically segments the prostate gland in MRI scans, reducing interpretation time per exam by 30%, according to the firm.

Fuse-AI plans to highlight Prostate.Carcinoma.ai at the Arab Health conference being held in Dubai, United Arab Emirates, from 29 January to 1 February.

Page 1 of 109
Next Page